跳至主要内容
临床试验/NL-OMON54811
NL-OMON54811招募中3 期

Tranexamic Acid to Prevent Operation in Chronic Subdural Hematoma - TORCH

Academisch Medisch Centrum0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age 50 years and above;
  • On CT confirmed cSDH;
  • Primary conservative treatment, based on clinical symptoms: Glasgow Coma
  • Scale score >=14, mNIHSS score <=4 and a stable neurological deficit (no new,
  • or progression of, symptoms between the assessment by the neurologist and the
  • assessment by the neurosurgeon).

排除标准

  • Primary surgical treatment based on one or more of the following symptoms or
  • parameters: medically intractable headache, midline shift >10mm, imminent death
  • within 24 hours;
  • Structural causes for subdural haemorrhage, e.g. arachnoid cysts, cortical
  • vascular malformations and a history of cranial surgery <1year;
  • Aneurysmal subarachnoid haemorrhage;
  • Active treatment for deep vein thrombosis, pulmonary embolism or cerebral
  • thrombosis (secondary prophylaxis is not considered to be active treatment);
  • Active intravascular clotting or disseminated intravascular coagulation;
  • Known hypersensitivity or allergy to TXA or to any of the ingredients;
  • History of a blood coagulation disorder (hypercoagulability disorder);
  • History of severe impairment of renal function (eGFR <30ml/min or serum
  • creatinine >150µmol/L);
  • Amanesis with signs of anemia (fatigue, headache, exercise intolerance,
  • weakness and pallor (conjunctival) dry skin);
  • History of epilepsy;
  • History of inability to safely swallow oral medication;
  • Inability to obtain informed consent from the patient or legal
  • representative, including language barrier.

研究者

相似试验